Abstract:Objective To explore the clinical efficacy of scopolamine injection assisted with azithromycin sequential therapy for mycoplasma pneumonia (MPP) in children and its effects on pulmonary function and cellular immune function. Methods Totally 178 cases of MPP patients admitted to Hunan Provincial People’s Hospital and Lhasa People's Hospital were randomly divided into the combined group (n?=?89) and the azithromycin group (n?= 89). The azithromycin group was given azithromycin sequential therapy and basic therapy, and the combined group was additionally given scopolamine injection via Feishu point. The clinical efficacy, pulmonary function and cellular immune function were compared between the two groups. Results After treatment, the clinical efficacy in the combined group was better than that in the azithromycin group (P?0.05). The forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1) and peak expiratory flow (PEF) in the combined group were significantly higher than those in the azithromycin group (P?0.05). The levels of serum CD3+, CD4+, and Clara cell secretory protein (CCSP) in the combined group were significantly higher than those in the azithromycin group (P?0.05). The levels of serum CD8+, monocyte chemoattractant protein-4 (MCP-4), cysteinyl leukotriene (CysLTs), and intercellular adhesion molecule-1 (ICAM-1) in the combined group were lower than those in the azithromycin group. Conclusions Scopolamine injection assisted with azithromycin sequential therapy for MMP children has significant efficacy, which can effectively improve pulmonary function and cellular immune function, and promote the rehabilitation of MMP children.